Skip to content

rTMS therapy for neurodevelopmental disorder

Specified Clinical Trial for efficacy and safety of rTMS for neurodevelopmental disorder

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs052250099
Enrollment
5
Registered
2025-09-01
Start date
2025-12-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodevelopmental disorder Neurodevelopmental Disorder

Interventions

repetitive transcranial magnetic stimulation Once per day, twice per week, 8 weeks
transcranial magnetic stimulation

Sponsors

Shimono Kuriko
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. patients with a diagnosis of Autism Spectrum Disorder (ASD) made by a pediatrician or psychiatrist using the DSM-5 (The Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders). Manual of Mental Disorders) by a pediatrician or psychiatrist. 2. have no organic abnormalities on MRI within 2 years prior to rTMS and have not previously been found to have epilepsy or afebrile seizures 3. Patients must have an intellectual quotient (IQ) of 60 or higher 4. right-handed diagnosed by the Edinburgh Handedness Inventory. 5. who are of age 8 to 30 years at the time of consent. 6. have been fully informed of the study and have provided informed consent from their parents or guardians and written assent from the patients themselves.

Exclusion criteria

Exclusion criteria: 1. those with metal present in the head other than the mouth. 2. those with a history of cardiac disease, gastrointestinal disease, chronic kidney disease, head trauma, or brain tumor. 3. those who have received a cardiac pacemaker, deep brain electrical stimulator, spinal cord stimulator, or drug therapy pump implantation. 4. those who have an organic abnormality in the cranium. 4. those with intracranial organic abnormalities (due to increased risk of seizure induction) 5. who have a history of convulsive disorders (febrile convulsions, epileptic seizures, epilepsy) 6. pregnant woman 7. who are deemed inappropriate by the responsible or subcontracting physician.

Design outcomes

Primary

MeasureTime frame
1) Number of cases which completed the treatment protocol 2) Number, frequency and severity of adverse events

Secondary

MeasureTime frame
1) Change from baseline in questionnaire scores of sensory abnormality and social responsiveness 2) APD test score

Contacts

Public ContactYoshiko Iwatani

The University of Osaka Hospital

handai.kokoro@gmail.com+81-6-6879-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026